logo

Aeglea Biotherapeutics, Inc. (AGLE)



Trade AGLE now with
  Date
  Headline
9/3/2019 6:06:33 AM Aeglea Announces Positive 20-Dose Data For Pegzilarginase In Patients With Arginase 1 Deficiency At 2019 SSIEM Symposium
8/29/2019 8:33:10 AM Aeglea BioTherapeutics To Present New 20-Dose Data For Pegzilarginase At 2019 SSIEM Symposium
2/6/2019 12:17:01 AM Aeglea BioTherapeutics Reports Pricing Of Public Offering Of 3.75 Mln Shares At $8/shr
11/8/2018 8:09:26 AM Aeglea BioTherapeutics Q3 Loss Per Share $0.54 Vs Loss $0.48 Last Year
10/22/2018 8:24:28 AM Aeglea BioTherapeutics Says Positive Interim Clinical Data For Pegzilarginase In Advanced Melanoma Patients At ESMO
10/17/2018 7:07:14 AM Aeglea BioTherapeutics Announces New Positive Interim Clinical Data For Ongoing Phase 1/2 Trial Of Pegzilarginase
10/10/2018 8:02:57 AM Aeglea BioTherapeutics To Present Interim Phase 1/2 Clinical Trial Data In Arginase 1 Deficiency At 2018 ASHG
10/1/2018 8:13:57 AM Aeglea BioTherapeutics: FDA Grants Rare Pediatric Disease Designation To Pegzilarginase For Arginase 1 Deficiency
9/17/2018 8:11:39 AM Aeglea BioTherapeutics To Deliver An Oral Presentation On AEB5100
8/9/2018 8:17:39 AM Aeglea BioTherapeutics Q2 Net Loss $9.4 Mln Vs Loss $6.6 Mln Last Year
7/19/2018 4:04:39 PM Aeglea BioTherapeutics Appoints Anthony Quinn As President And CEO
7/16/2018 8:06:49 AM Aeglea BioTherapeutics Appoints Bryan Lawlis To Board Of Directors
6/29/2018 4:03:20 PM Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/8/2018 8:07:56 AM Aeglea BioTherapeutics Q1 Loss Per Share $0.49 Vs Loss $0.47 Last Year
4/18/2018 11:28:07 PM Aeglea BioTherapeutics Prices Underwritten Public Offering Of 4.50 Mln Shares At $8.00/shr
4/17/2018 4:04:55 PM Aeglea BioTherapeutics Announces Proposed Public Offering Of Common Stock
4/12/2018 7:20:49 AM Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Of Pegzilarginase In Arginase 1 Deficiency Patients